Literature DB >> 29043881

Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines.

Darius Juskevicius1, Anne Müller2, Hind Hashwah2, Pontus Lundberg3, Alexandar Tzankov1, Thomas Menter1.   

Abstract

Investigation of cancer cell lines is important for oncology research to characterize and understand mechanisms of cellular signaling and survival strategies in cancer. We analyzed the mutational profile of 11 diffuse large B-cell lymphoma (DLBCL) cell lines using a customized high throughput sequencing panel. We compared our data to previously published mutation data to better characterize these cell lines and establish consensus on the mutational status of some functionally relevant genes. With our targeted sequencing approach we detected 61 somatic mutations. The most frequently affected gene was TP53. MYD88 mutations were only seen in activated B-cell like cell lines. Overall comparison across different datasets revealed that just around 38% of mutations are reliable and can be validated by at least two independent observations whereas 24% of mutations could not be validated. Our analysis reveals considerable discrepancies regarding the mutational profile of some well-established cell lines.

Entities:  

Keywords:  CCLE; COSMIC; DLBCL; TP53; cell lines; mutational profile; next generation sequencing

Mesh:

Substances:

Year:  2017        PMID: 29043881     DOI: 10.1080/10428194.2017.1387903

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

1.  Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma.

Authors:  Anna Stelling; Cheuk-Ting Wu; Katrin Bertram; Hind Hashwah; Alexandre P A Theocharides; Markus G Manz; Alexandar Tzankov; Anne Müller
Journal:  Blood Adv       Date:  2019-10-22

2.  The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma.

Authors:  Hind Hashwah; Katrin Bertram; Kristin Stirm; Anna Stelling; Cheuk-Ting Wu; Sabrina Kasser; Markus G Manz; Alexandre P Theocharides; Alexandar Tzankov; Anne Müller
Journal:  EMBO Mol Med       Date:  2019-09-12       Impact factor: 12.137

3.  Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma.

Authors:  Forum Kayastha; Noah B Herrington; Bandish Kapadia; Anirban Roychowdhury; Nahid Nanaji; Glen E Kellogg; Ronald B Gartenhaus
Journal:  Mol Med       Date:  2022-09-04       Impact factor: 6.376

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.